Go back to newswire list

Carl Zeiss Meditec AG

ISIN: DE0005313704

WKN: 531370

22 January 2026 09:50AM

EQS-Adhoc: Carl Zeiss Meditec AG: Q1 FY 2025/26 earnings clearly below past year - FY 2025/26 guidance will likely not be achieved

Carl Zeiss Meditec AG · ISIN: DE0005313704 · EQS - adhoc news

Country: Germany · Primary market: Germany · EQS NID: 2264262

EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Quarter Results/Change in Forecast
Carl Zeiss Meditec AG: Q1 FY 2025/26 earnings clearly below past year - FY 2025/26 guidance will likely not be achieved

22-Jan-2026 / 09:50 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

Q1 FY 2025/26 earnings clearly below past year - FY 2025/26 guidance will likely not be achieved

Jena, January 22, 2026

In the first 3 months of fiscal year (FY) 2025/26 ending December 31, 2025, Carl Zeiss Meditec AG (ISIN: DE0005313704) recorded preliminary revenue of € 467 million (prior year: € 490 million). The revenue decline was mainly caused by negative currency effects. Preliminary operating profit (Earnings before interest, taxes and amortization of intangible assets from purchase price allocations = EBITA) amounted to € 8 million (prior year: € 35 million).

Several reasons for softer business performance in the first 3 months can be identified: the exceptionally strong equipment deliveries in the last month of FY 2024/25, which resulted in a softer start to the new FY; significant currency headwinds; the revenue loss from a bifocal intraocular (IOL) in China following its withdrawal from the volume-based-procurement tender, as previously disclosed in the FY 2024/25 earnings call on December 11, 2025; an increasingly weak investment environment in the Americas region amid heightened geopolitical volatility; and a later start to the seasonal peak for refractive treatment packs by hospitals in China due to the late timing of the Chinese New Year holidays. In addition, the upcoming new nation-wide volume-based procurement tender for the IOL business in China is expected to cause significant price erosion due to an increased level of Chinese local competition.

Given the current high level of uncertainties surrounding geopolitical developments, trade barriers and regulatory changes, previous FY 2025/26 guidance will likely not be achieved and is currently under review, while among other factors the outcomes of the IOL re-registration process and new nation-wide volume-based-procurement tender in China as well as the winter seasonal peak for refractive treatment packs are pending (previous guidance: around € 2.3 billion in revenue and an EBITA margin (EBITA/Revenue) of 12.5%). Management will present an update on further re-organization and expense measures together with refined FY 2025/26 guidance as soon as possible and no later than the 6-month earnings call on May 12, 2026.

The quarterly statement for 3M 2025/26 will be published on February 12, 2026.

Contact for investors and press

Sebastian Frericks

Head of Group Finance & Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: investors.med@zeiss.com

End of Inside Information

22-Jan-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

Language:	English
Company:	Carl Zeiss Meditec AG
	Göschwitzer Str. 51-52
	07745 Jena, Germany
	Germany
Phone:	+49 (0)3641 220-0
Fax:	+49 (0)3641 220-112
E-mail:	investors.meditec@zeiss.com
Internet:	www.zeiss.de/meditec-ag/ir
ISIN:	DE0005313704
WKN:	531370
Indices:	MDAX, TecDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
EQS News ID:	2264262


End of Announcement	EQS News Service

2264262 22-Jan-2026 CET/CEST

More Research

Company related KPIs

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
	2020	2021	2022	2023	2024	2025e	2026e
Sales¹	1.335,45	1.646,79	1.902,84	2.089,30	2.066,13	2.227,65	2.100,00
EBITDA^1,2	237,98	435,20	466,65	422,19	327,22	349,70	252,00
EBITDA-Margin³	17,82	26,43	24,52	20,21	15,84	15,70	12,00
EBIT^1,4	177,55	373,61	396,88	348,12	194,45	223,32	160,00
EBIT-Margin⁵	13,30	22,69	20,86	16,66	9,41	10,03	7,62
Net Profit (Loss)¹	123,42	237,52	295,91	292,01	180,15	142,35	70,00
Net-Margin⁶	9,24	14,42	15,55	13,98	8,72	6,39	3,33
Cashflow^1,7	178,53	362,66	188,20	250,86	247,32	209,86	245,00
Earnings per share⁸	1,37	2,64	3,29	3,25	2,01	1,61	0,78
Dividend per share⁸	0,50	0,90	1,10	1,10	0,60	0,55	0,45

Quelle: boersengefluester.de and Company information

Explanation

¹ in Mio. Euro; ² EBITDA = Earnings before interest, taxes, depreciation and amortisation; ³ EBITDA in relation to sales; ⁴ EBIT = Earnings before interest and taxes; ⁵ EBIT in relation to sales; ⁶ Net profit (-loss) in relation to sales; ⁷ Cashflow from operations; ⁸ in Euro; Source: boersengefluester.de

Auditor: PricewaterhouseCoopers

Company Snapshot

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Carl Zeiss Meditec
WKN	ISIN	Legal Type	Marketcap	IPO	Recommendation	Plus Code
531370	DE0005313704	AG	2.477,50 Mio €	22.03.2000	Halten	9F2HVHPW+8C

* * *

PE 2027e	PE 10Y-Ø	BGFL-Ratio	Shiller-PE	PB	PCF	KUV
18,47	32,95	0,56	12,60	1,20	11,81	1,11

Dividends

Dividend '2023 in €	Dividend '2024 in €	Dividend '2025e in €	Div.-Yield '2025e in %
1,10	0,60	0,55	1,99%

Financial calendar

Annual General Meeting	Q1-figures	Q2-figures	Q3-figures	Annual press conference
26.03.2026	12.02.2026	12.05.2026	06.08.2026	11.12.2025

Performance

Distance 60-days-line	Distance 200-days-line	Performance YtD	Performance 52 weeks	IPO	Last Price (EoD) -3,75% 27,70 € ATH 202,00 €
-32,79%	-42,55%	-30,75%	-51,40%	-4,48%	Last Price (EoD) -3,75% 27,70 € ATH 202,00 €

LEI: 529900GRL4MZ8NMOOK95

Social media-channel

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.

EQS-Adhoc: Carl Zeiss Meditec AG: Q1 FY 2025/26 earnings clearly below past year - FY 2025/26 guidance will likely not be achieved

Quick Links

Network

Partner

Contact

EQS-Adhoc: Carl Zeiss Meditec AG: Q1 FY 2025/26 earnings clearly below past year - FY 2025/26 guidance will likely not be achieved

Would you like to see fewer adverts? Simply register for a user account. Registration is free and significantly reduces the number of adverts.

Quick Links

Network

Partner

Contact